🔗 Share this article

Given that the United States undertakes sweeping adjustments to its immunization guidelines, a particular individual has emerged somewhat surprisingly: Tracy Beth Høeg, an American of Danish descent physician and public health researcher who initially gained attention by casting doubt on COVID-19 vaccinations in the pandemic and has concentrated on possible fatalities following Covid vaccination in her recent tenure at the US Food and Drug Administration (FDA).

Proposed Changes to Pediatric Vaccine Program

Agency leaders had intended to reveal major revisions to the pediatric vaccination calendar earlier this month, bringing the US with the Danish immunization schedule, sources say – a substantial departure that would place the US out of alignment with many the world with insufficient data for improved outcomes. The announcement has been postponed until the next year.

Rather than the director of the vaccine center, Tracy Beth Høeg is set to present at the meeting. She was just designated acting director of the FDA’s drug evaluation center, the fifth individual to head the division this year.

A Shift at the FDA

The acting appointment may indicate a closer partnership between the pharmaceutical and vaccine divisions as Dr. Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it signals a increased emphasis upon dismantling previously authorized vaccines at the FDA.

Høeg has repeatedly called for ending specific childhood immunization guidelines in the US in order to be more in line with Denmark, a nation with nationalized medicine and a citizenry roughly the size of the state of Wisconsin.

To date comments, she has continued to focus on vaccination policy – typically the domain of Prasad, director of the FDA’s CBER – instead of pharmaceutical oversight.

Doubts Over Background

Høeg has no obvious background in drug development, oversight or leadership, which has been customary for previous heads of the CBER. She has been employed at the FDA as a key advisor to the FDA chief and CBER since spring.

“She doesn’t seem to have the requisite experience” for overseeing the pharmaceutical oversight division, remarked Jonathan Howard. “She has not conducted a randomized controlled trial. She is not versed in managing a large organization. She has no expertise in drug approvals.”

Former directors of the center would “grasp legal statutes and the science of pharmaceutical innovation”, said a former acting FDA commissioner. “Frankly, she lacks the sort of resume that former directors who headed CBER have had.”

The drug center has an immense portfolio at the agency, the former commissioner pointed out.

“Everybody just pays attention on the new drug program, but the off-patent medication office authorizes numerous generic medications. There’s a biosimilars division, non-prescription drug unit and other areas, and every single one have to be looked after,” she explained. “The thing you neglect, that is precisely what that I always told people is going to come back to haunt you.”

There is also, a significant management component to the position, which oversees more than 5,000 personnel. “It’s a enormous leadership role, if you perform it correctly,” the former official added.

Official Statement and Controversial Initiatives

In response to concerns about Dr. Høeg's credentials and whether this appointment indicates more teamwork among regulatory chiefs on immunizations, a representative responded that the “inquiries rely on flawed presumptions”.

“Her resume is consistent with the functions of her job,” the spokesperson explained, citing the months Dr. Høeg spent counseling the FDA commissioner on “pharmaceutical safety and regulatory science, including predictive safety algorithms and shot safety tracking”.

As acting director, Dr. Høeg assumes responsibility for the agency head's recently launched expedited review system, a disputed expedited therapy clearance system that allegedly troubled her former heads. “By what process are these medications being picked for this fast-track system? Who is making the choices?” Dr. Howard questioned. “There’s a lot of secrecy happening at the FDA right now.”

In general, he said, “the FDA seems to be moving towards less stringent rules of all drugs, except for shots.”

Established Track Record on Immunizations

Regarding vaccines, Høeg has a more established, if concerning, history, some experts said. She authored a analysis using unverified public submissions to estimate the incidence of heart inflammation following COVID-19 vaccination. She counseled the Florida chief medical officer Dr. Joseph Ladapo, who allegedly have altered data to suggest COVID-19 vaccines are more dangerous than they are.

Part of her “wish list” for the incoming government included changing guidelines for new vaccines and halting “optional” immunizations, she stated after the election on a audio program. At the FDA, Høeg has reportedly suggested excluding adolescent males from getting Covid vaccinations.

“She’s an thorough ideologue who begins with her beliefs and works backwards to accommodate the evidence in a extremely deceptive, fraudulent fashion,” Howard stated.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg aligned with fellow contrarians, {like|